drugset / Trial / NCT01940926

68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis

NCT01940926 ↗

Phase 0 Unknown 50 enrolled Peking Union Medical College Hospital
NaSingle-groupOpen-labelDiagnostic

Summary

This is an open-label positron emission tomography/computed tomography ( PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-BNOTA-PRGD2 in rheumatoid arthritis (RA) patients. A single dose of nearly 111 MBq 68Ga-BNOTA-PRGD2 (≤ 40 µg BNOTA-PRGD2) will be intravenously injected into patients with RA. Visual and semiquantitative method will be used to assess the PET/CT images. Whole body 18F-FDG PET/CT will be performed for comparison.

Timeline

Start
2012-02
Primary completion
2017-11
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-BNOTA-PRGD2 Diagnostic / imaging agent 111 mbq Intravenous

Indications